Schrödinger, Inc. Reports Second Quarter 2020 Financial Results and Business Updates
Total revenue of
Software revenue of
New strategic agreements with Thermo Fisher and Viva Biotech
Rapid progress across internal pipeline; three programs in late-stage discovery
Conference call today,
“We made excellent progress during the second quarter across our entire business, including growing our software business, advancing our drug discovery programs, and developing new platform capabilities,” said Schrödinger CEO
Second Quarter Financial Results
Revenue was
Software revenue was
Gross profit reached
Operating expenses for the second quarter of 2020 were
Other income, which includes gains on equity investments and changes in fair value of such investments, was
Net loss, after adjusting for non-controlling interests, was
Schrödinger ended the second quarter with cash, cash equivalents, restricted cash and marketable securities of
“We are executing on our strategy to drive growth in our software business and rapidly progress our drug discovery programs," said Schrödinger CFO
Second Quarter Business Updates
Driving growth in software business
-
$20.9 million in software revenue in the second quarter of 2020, representing 44% growth compared to the second quarter of 2019 - Growth in software revenue was driven by the addition of new customers, expanded adoption of our software solutions by existing customers, and growth in both life sciences and materials science
Creating value from biotech equity stakes
-
Petra Pharma was acquired by a third party, resulting in a$4.6 million cash distribution to us, as well as the potential for future earnouts. We recognized a$4.2 million gain on the distribution -
Appreciation of shares in Morphic Holding resulted in a non-cash gain of
$10.3 million - Anticipated non-cash gain in the third quarter, which will be based on the market value of our 422,425 shares in Relay Therapeutics, which completed its IPO in July
Expanding platform reach
-
Drug Discovery – Entered into two strategic partnerships to expand the availability of high-resolution structures of protein complexes, which will increase the number of targets available for structure-based drug design
- Viva Biotech - to access new x-ray crystal structures for high-value targets
- Thermo Fisher Scientific - to leverage the capabilities of the leader in cryo-EM to obtain structures of protein complexes that may not be amenable to x-ray crystallography
-
Materials Science – Entered into three-year agreement with
Gates Ventures to develop and apply atomistic simulation methods to improve battery performance
Advancing collaborative and wholly-owned drug discovery programs
- 12 internal and collaboration programs in late-stage discovery, including three wholly-owned programs – MALT1, CDC7 and WEE1, targeting solid tumors and hematological malignancies
- 237 billion compounds explored computationally during the first half of 2020 across collaborative and internal programs enabling several programs to advance from program initiation to lead optimization in just months, instead of potentially years
Advancing the underlying science
- Significant increase in the scale and accuracy of chemical space exploration to accelerate the identification of higher quality drug candidates
- Improved methods for determination of cryo-EM structures of protein/ligand complexes helping to expand the reach of our technology
- Improvements to the accuracy of binding affinity predictions from FEP+ through enhanced modeling of water molecules
- New method for calculating absolute binding affinities using FEP+ to improve hit rates in virtual screening
“We are excited by the scientific advances and progress we have made on behalf of all our stakeholders,” said
Business Impact of COVID-19 Pandemic
While we did not see material impacts to our business from the COVID-19 pandemic during the first half of 2020, we have identified certain market risks that, if they materialize, could affect the growth of our software business and the timing of our drug discovery revenues for at least the remainder of 2020. Some of our software customers may experience increasing budgetary pressures, which may cause them to delay or reduce purchases. In addition, our sales force has limited in-person interactions, and their ability to attend industry conferences and events that promote and expand knowledge of our company and platform has been hampered. Relative to our drug discovery programs, certain programs, particularly ones that are in clinical studies or preparing to enter clinical studies, could be delayed which could result in delays in achieving milestones and related revenue. While there remains uncertainty about the extent of the effect of the COVID-19 pandemic, we do not envision a long-term impact from the COVID-19 pandemic on our ability to execute on our long-term strategy.
Webcast and Conference Call Information
Schrödinger will host a conference call to discuss its second quarter financial results on
About Schrödinger
Schrödinger’s industry-leading computational platform facilitates the research efforts of biopharmaceutical and industrial companies, academic institutions and government laboratories worldwide. Schrödinger also has wholly-owned and collaborative drug discovery programs in a broad range of therapeutic areas.
Schrödinger is deeply committed to investing in the science and talent that drive its computational platform. Schrödinger was founded in 1990, has over 400 employees and is engaged with customers and collaborators in more than 70 countries. To learn more visit www.schrodinger.com. Follow us on LinkedIn, https://www.linkedin.com/company/schr-dinger/, and Twitter, https://twitter.com/schrodinger.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to those regarding our expectations about the speed and capacity of our computational platform, our plans to continue to invest in research and our strategic plans to accelerate the growth of our software business and advance our collaborative and internal drug discovery programs, our ability to improve and advance the science underlying our platform, including through these use of new technologies, our expectations regarding the increase in the fair value of our equity stake in Relay Therapeutics, our expectations related to the use of our cash, cash equivalents, and marketable securities as well as our expectations related to the COVID-19 pandemic’s impact on our business. Statements including words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," "would" and statements in the future tense are forward-looking statements. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Actual results may differ materially from those described in these forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond our control, including the demand for our software solutions, our ability to further develop our computational platform, our reliance upon third-party providers of cloud-based infrastructure to host our software solutions, our reliance upon our third-party drug discovery collaborators, the ability to retain and hire key personnel and the direct and indirect impacts of the ongoing COVID-19 pandemic on our business and other risks detailed under the caption "Risk Factors" and elsewhere in our
|
Condensed Consolidated Statements of Operations (Unaudited) |
|
|||||||||||||||
|
(in thousands, except for share and per share amounts) |
|
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
|
|
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
||||
|
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Software products and services |
|
$ |
20,900 |
|
|
$ |
14,482 |
|
|
$ |
44,712 |
|
|
$ |
33,087 |
|
|
Drug discovery |
|
|
2,192 |
|
|
|
4,528 |
|
|
|
4,554 |
|
|
|
6,664 |
|
|
Total revenues |
|
|
23,092 |
|
|
|
19,010 |
|
|
|
49,266 |
|
|
|
39,751 |
|
|
Cost of revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Software products and services |
|
|
3,862 |
|
|
|
3,671 |
|
|
|
7,863 |
|
|
|
6,804 |
|
|
Drug discovery |
|
|
5,647 |
|
|
|
5,488 |
|
|
|
12,195 |
|
|
|
10,092 |
|
|
Total cost of revenues |
|
|
9,509 |
|
|
|
9,159 |
|
|
|
20,058 |
|
|
|
16,896 |
|
|
Gross profit |
|
|
13,583 |
|
|
|
9,851 |
|
|
|
29,208 |
|
|
|
22,855 |
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
16,657 |
|
|
|
9,531 |
|
|
|
30,357 |
|
|
|
17,969 |
|
|
Sales and marketing |
|
|
4,362 |
|
|
|
5,343 |
|
|
|
9,151 |
|
|
|
10,436 |
|
|
General and administrative |
|
|
9,651 |
|
|
|
8,940 |
|
|
|
18,587 |
|
|
|
14,026 |
|
|
Total operating expenses |
|
|
30,670 |
|
|
|
23,814 |
|
|
|
58,095 |
|
|
|
42,431 |
|
|
Loss from operations |
|
|
(17,087 |
) |
|
|
(13,963 |
) |
|
|
(28,887 |
) |
|
|
(19,576 |
) |
|
Other income: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain on equity investment |
|
|
4,156 |
|
|
|
— |
|
|
|
4,156 |
|
|
|
— |
|
|
Change in fair value |
|
|
8,359 |
|
|
|
12,661 |
|
|
|
5,280 |
|
|
|
12,034 |
|
|
Interest income |
|
|
570 |
|
|
|
524 |
|
|
|
1,269 |
|
|
|
962 |
|
|
Total other income |
|
|
13,085 |
|
|
|
13,185 |
|
|
|
10,705 |
|
|
|
12,996 |
|
|
Loss before income taxes |
|
|
(4,002 |
) |
|
|
(778 |
) |
|
|
(18,182 |
) |
|
|
(6,580 |
) |
|
Income tax expense (benefit) |
|
|
64 |
|
|
|
(51 |
) |
|
|
155 |
|
|
|
(5 |
) |
|
Net loss |
|
|
(4,066 |
) |
|
|
(727 |
) |
|
|
(18,337 |
) |
|
|
(6,575 |
) |
|
Net loss attributable to noncontrolling interest |
|
|
(716 |
) |
|
|
(227 |
) |
|
|
(1,161 |
) |
|
|
(281 |
) |
|
Net loss attributable to Schrödinger common and limited common stockholders |
|
$ |
(3,350 |
) |
|
$ |
(500 |
) |
|
$ |
(17,176 |
) |
|
$ |
(6,294 |
) |
|
Net loss per share attributable to Schrödinger common and limited common stockholders, basic and diluted: |
|
$ |
(0.05 |
) |
|
$ |
(0.01 |
) |
|
$ |
(0.33 |
) |
|
$ |
(0.14 |
) |
|
Weighted average shares used to compute net loss per share attributable to Schrödinger common and limited common stockholders, basic and diluted: |
|
|
63,296,366 |
|
|
|
44,495,701 |
|
|
|
51,981,647 |
|
|
|
44,493,667 |
|
|
Condensed Consolidated Balance Sheets (Unaudited) |
|
|||||||
|
(in thousands, except for share and per share amounts) |
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
Assets |
|
|
|
|
|
|
||
|
Current assets: |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
110,380 |
|
|
$ |
25,986 |
|
|
Restricted cash |
|
|
500 |
|
|
|
500 |
|
|
Marketable securities |
|
|
173,646 |
|
|
|
59,844 |
|
|
Accounts receivable, net of allowance for doubtful accounts of |
|
|
13,849 |
|
|
|
18,676 |
|
|
Unbilled and other receivables |
|
|
3,345 |
|
|
|
7,062 |
|
|
Prepaid expenses |
|
|
5,294 |
|
|
|
6,468 |
|
|
Total current assets |
|
|
307,014 |
|
|
|
118,536 |
|
|
Property and equipment, net |
|
|
5,837 |
|
|
|
6,268 |
|
|
Equity investments |
|
|
22,680 |
|
|
|
15,366 |
|
|
Right of use assets |
|
|
11,918 |
|
|
|
12,762 |
|
|
Other assets |
|
|
2,102 |
|
|
|
2,338 |
|
|
Total assets |
|
$ |
349,551 |
|
|
$ |
155,270 |
|
|
Liabilities, Convertible Preferred Stock, and Stockholders’ Equity (Deficit) |
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
5,523 |
|
|
$ |
3,524 |
|
|
Accrued payroll, taxes, and benefits |
|
|
5,757 |
|
|
|
7,034 |
|
|
Deferred revenue |
|
|
23,138 |
|
|
|
25,054 |
|
|
Lease liabilities |
|
|
5,839 |
|
|
|
5,584 |
|
|
Other accrued liabilities |
|
|
2,791 |
|
|
|
3,824 |
|
|
Total current liabilities |
|
|
43,048 |
|
|
|
45,020 |
|
|
Deferred revenue, long-term |
|
|
1,979 |
|
|
|
2,205 |
|
|
Lease liabilities, long-term |
|
|
7,777 |
|
|
|
8,888 |
|
|
Other liabilities, long-term |
|
|
600 |
|
|
|
900 |
|
|
Total liabilities |
|
|
53,404 |
|
|
|
57,013 |
|
|
Commitments and contingencies |
|
|
|
|
|
|
|
|
|
Convertible preferred stock: |
|
|
|
|
|
|
|
|
|
Series E convertible preferred stock, |
|
|
— |
|
|
|
109,270 |
|
|
Series D convertible preferred stock, |
|
|
— |
|
|
|
22,000 |
|
|
Series C convertible preferred stock, |
|
|
— |
|
|
|
19,844 |
|
|
Series B convertible preferred stock, |
|
|
— |
|
|
|
9,840 |
|
|
Series A convertible preferred stock, |
|
|
— |
|
|
|
30,626 |
|
|
Total convertible preferred stock |
|
|
— |
|
|
|
191,580 |
|
|
Stockholders' equity (deficit): |
|
|
|
|
|
|
|
|
|
Common stock, |
|
|
501 |
|
|
|
61 |
|
|
Limited common stock, |
|
|
132 |
|
|
|
— |
|
|
Additional paid-in capital |
|
|
417,032 |
|
|
|
11,655 |
|
|
Accumulated deficit |
|
|
(122,272 |
) |
|
|
(105,096 |
) |
|
Accumulated other comprehensive income |
|
|
727 |
|
|
|
16 |
|
|
Total stockholders’ equity (deficit) of Schrödinger stockholders |
|
|
296,120 |
|
|
|
(93,364 |
) |
|
Noncontrolling interest |
|
|
27 |
|
|
|
41 |
|
|
Total stockholders’ equity (deficit) |
|
|
296,147 |
|
|
|
(93,323 |
) |
|
Total liabilities, convertible preferred stock, and stockholders’ equity (deficit) |
|
$ |
349,551 |
|
|
$ |
155,270 |
|
|
Condensed Consolidated Statements of Cash Flows (Unaudited) |
|
|||||||
|
(in thousands) |
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended |
|
|||||
|
|
|
2020 |
|
|
2019 |
|
||
|
Cash flows from operating activities: |
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(18,337 |
) |
|
$ |
(6,575 |
) |
|
Adjustments to reconcile net loss to net cash used in |
|
|
|
|
|
|
|
|
|
operating activities: |
|
|
|
|
|
|
|
|
|
Gain on equity investments |
|
|
(4,156 |
) |
|
|
— |
|
|
Noncash revenue from equity investments |
|
|
(169 |
) |
|
|
(92 |
) |
|
Fair value adjustments |
|
|
(5,280 |
) |
|
|
(12,034 |
) |
|
Depreciation |
|
|
1,758 |
|
|
|
1,793 |
|
|
Stock-based compensation |
|
|
4,504 |
|
|
|
1,051 |
|
|
Noncash research and development expenses |
|
|
1,147 |
|
|
|
227 |
|
|
Noncash investment accretion |
|
|
(205 |
) |
|
|
(212 |
) |
|
Decrease (increase) in assets: |
|
|
|
|
|
|
|
|
|
Accounts receivable, net |
|
|
4,827 |
|
|
|
233 |
|
|
Unbilled and other receivables |
|
|
4,126 |
|
|
|
1,044 |
|
|
Reduction in the carrying amount of right of use assets |
|
|
2,622 |
|
|
|
1,551 |
|
|
Prepaid expenses and other assets |
|
|
(447 |
) |
|
|
1,149 |
|
|
Increase (decrease) in liabilities: |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
|
1,999 |
|
|
|
123 |
|
|
Accrued payroll, taxes, and benefits |
|
|
(1,277 |
) |
|
|
(35 |
) |
|
Deferred revenue |
|
|
(1,973 |
) |
|
|
1,779 |
|
|
Lease liabilities |
|
|
(2,634 |
) |
|
|
(1,547 |
) |
|
Other accrued liabilities |
|
|
(1,334 |
) |
|
|
2,682 |
|
|
Net cash used in operating activities |
|
|
(14,829 |
) |
|
|
(8,863 |
) |
|
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
|
Purchases of property and equipment |
|
|
(1,327 |
) |
|
|
(1,393 |
) |
|
Purchases of equity investments |
|
|
(2,869 |
) |
|
|
— |
|
|
Distribution from equity investment |
|
|
4,582 |
|
|
|
— |
|
|
Purchases of marketable securities |
|
|
(177,694 |
) |
|
|
(65,504 |
) |
|
Proceeds from sale and maturity of marketable securities |
|
|
64,808 |
|
|
|
12,325 |
|
|
Net cash used in investing activities |
|
|
(112,500 |
) |
|
|
(54,572 |
) |
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
|
Issuances of common stock upon initial public offering, net |
|
|
211,491 |
|
|
|
— |
|
|
Issuances of Series E preferred stock, net |
|
|
— |
|
|
|
29,893 |
|
|
Issuances of common stock upon stock option exercise |
|
|
232 |
|
|
|
180 |
|
|
Contribution by noncontrolling interest |
|
|
— |
|
|
|
100 |
|
|
Net cash provided by financing activities |
|
|
211,723 |
|
|
|
30,173 |
|
|
Net increase (decrease) in cash and cash equivalents and restricted cash |
|
|
84,394 |
|
|
|
(33,262 |
) |
|
Cash and cash equivalents and restricted cash, beginning of period |
|
|
26,486 |
|
|
|
77,716 |
|
|
Cash and cash equivalents and restricted cash, end of period |
|
$ |
110,880 |
|
|
$ |
44,454 |
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure of cash flow and noncash information |
|
|
|
|
|
|
|
|
|
Cash paid for income taxes |
|
$ |
149 |
|
|
$ |
43 |
|
|
Supplemental disclosure of non-cash investing and financing activities |
|
|
|
|
|
|
|
|
|
Purchases of property and equipment |
|
|
— |
|
|
|
26 |
|
|
Acquisitions of right of use assets in exchange for lease obligations |
|
|
1,778 |
|
|
|
464 |
|
|
Right of use assets recognized on adoption |
|
|
— |
|
|
|
16,475 |
|
|
Reclass of deferred financing costs to additional paid in capital |
|
|
1,858 |
|
|
|
— |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20200810005177/en/
Media Contact:
Ten
stephanie@tenbridgecommunications.com
617-581-9333
Investor Contact:
christina.tartaglia@sternir.com
212-362-1200
Source: Schrödinger, Inc.